Bharucha David's Form 4 filing
Milestone Pharmaceuticals Inc. (MIST) · filed Jan 28, 2026
- Accession no.
- 0001910985-26-000003
- Filed
- Jan 28, 2026
- Trade date
- Dec 12, 2025-Jan 26, 2026
- Filing delay
- 47 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $158.2K. It was filed 47 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bharucha DavidCIK 0001910985 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | Common Shares | AGrant or awardAcquired | +100,000 | – | – | 163,333 | Direct | |
| Dec 15, 2025 | Common Shares | SSaleDisposed | −58,007 | $2.32 | −$134,576.24 | 105,326 | Direct | |
| Jan 26, 2026 | Common Shares | MOption exerciseAcquired | +20,100 | – | – | 125,426 | Direct | |
| Jan 26, 2026 | Common Shares | SSaleDisposed | −12,245 | $1.93 | −$23,632.85 | 113,181 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | Common Shares | AGrant or awardAcquired | +100,000 | $0.00 | $0 | 100,000 | Direct | |
| Jan 26, 2026 | Common Shares | MOption exerciseDisposed | −20,100 | $0.00 | $0 | 60,300 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.